Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of Acute Psychomotor Agitation Measures in Schizophrenia and Bipolar Disorder
NCT07116694Phase 2Completed
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- Jun 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dexmedetomidine in psychomotor agitation, sponsored by BioXcel Therapeutics, Inc. Primary endpoints: Informant and Clinician ratings comparison at 2 hours and Informant training materials assessment at 7 days. Started Jun 2025; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
psychomotor agitation
Beyond the preview
Go deeper on NCT07116694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116694.